Algiax raises €4.0M Series B round
23 March 2016· Erkrath, Germany· health, pharmaceuticals, biotech, b2b, deep_hardware, drug_discovery
The funding is intended to support the clinical Phase IIa study of the lead candidate AP-157 for the treatment of peripheral neuropathic pain.
Investors
LeadHigh-Tech Gründerfonds
Also participating
NRW.Bank
About Algiax
Stage
Series B
Headquarters
Erkrath, Germany
Founded
2011
Team Size
6–20
Sectors
healthpharmaceuticalsbiotechb2bdeep_hardwaredrug_discovery
Source: https://www.algiax.com/algiax-pharmaceuticals-receives-e-4-million-in-a-third-financing-round/